Bluewater Research

Surface Ophthalmics, originally founded as Bluewater Research, is a clinical-stage biotechnology company focused on developing innovative therapies for ocular surface diseases. The company utilizes its proprietary Klarity delivery vehicle, a patented technology designed to improve the solubility, stability, and residence time of topical ophthalmic medications. Its lead product candidates include SURF-100, a combination of mycophenolate sodium and cyclosporine, and SURF-200, a unique formulation of betamethasone sodium phosphate. These programs target significant unmet needs in the treatment of dry eye disease and chronic ocular surface pain. By optimizing established active pharmaceutical ingredients with advanced delivery systems, Surface Ophthalmics aims to provide more effective and better-tolerated options for patients. The company is led by a management team and board with extensive experience in the ophthalmic industry.